Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

CMS payment group: Jeffrey B. Rich, M.D., will be the new director of CMS' Center for Medicare Management starting Feb. 18. CMM is charged with establishing and overseeing the agency's payment policies and is primarily responsible for implementing ongoing reforms including durable medical equipment competitive bidding and pay-for-performance. Rich is a practicing cardiothoracic surgeon and director-at-large for the Society of Thoracic Surgeons. He has been involved in pay-for-performance initiatives through his work with the National Quality Forum, the Hospital Quality Alliance and the AQA (formerly known as the Ambulatory Care Quality Alliance). CMM has not had a permanent director since Herb Kuhn moved up in ranks to deputy administrator of CMS in late 2006 (1"The Gray Sheet" March 5, 2007, p. 7). Current CMM Acting Director Liz Richter will become the group's permanent deputy

You may also be interested in...



People In Brief

Biomet names CEO: Former Abbott exec Jeffrey Binder succeeds interim CEO Daniel Hann in the top spot at Biomet on Feb. 26. Hann, who will stay with Biomet as executive VP of administration and a member of the board, was named acting CEO in March 2006 when co-founder Dane Miller abruptly resigned (1"The Gray Sheet" April 3, 2006, In Brief). Binder takes over shortly after Biomet agreed to be acquired by an investor consortium for $10.9 billion, or $44 a share (2"The Gray Sheet" Jan. 2007, p. 6). The 15-year orthopedics industry veteran is no stranger to transitioning leadership. Binder supervised the integration of DePuy Orthopedics into Johnson & Johnson in 1998 and served as president of DePuy's joint reconstruction and trauma group until 2000, when he became CEO of Spinal Concepts. That firm was acquired by Abbott in 2003 (3"The Gray Sheet" June 9, 2003, p. 25). Binder led Abbott Spine until Jan. 2006, when he was named VP diagnostic operations. Abbott recently sold its core in vitro diagnostics unit to GE for $8.13 billion (4"The Gray Sheet" Jan. 22, 2007, p. 3)...

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

UsernamePublicRestriction

Register

OM002075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel